Join us at the World ADC London 2024 conference in London, UK from March 13-14! Our Chief Scientific Officer and Senior Director of New Drug Development, Dr. Benny Yang, will be presenting "RenBiologics is at the forefront of advancing bispecific ADCs and nanobody ADCs" at 12:30 PM on March 13th.
Speaker Session
Presenter: Dr. Benny Yang, Chief Scientific Officer and Senior Director of New Drug Development of Biocytogen
Date and Time: March 13th, 12:30 PM GMT
Title: RenBiologics is at the forefront of advancing bispecific ADCs and nanobody ADCs
Biocytogen’s antibody Business Development & Licensing team will present 2 posters, introducing our bispecific ADC asset BCG033 (PTK7 x TROP2), and our tumor-associated antigen (TAA) antibody library, consisting of antibodies against approximately 200 targets with a proprietary linker/payload for ADC plug-and-play.
Posters Session
Date and Time: March 13th, 12:30 PM GMT
Antibody-drug conjugates are the moment now, with the past year celebrating new approvals, positive clinical data, and over 300 ADCs in various stages of clinical development promising a bright future for these therapies in the fight against cancer.
As the field enters a new era with pipelines continuing to expand for 2024 and beyond, the 14th World ADC London is a opportunity to reflect on the drivers of success behind the superstar drugs ENHERTU and ELAHARE, discuss exciting novel approaches to drug-conjugate design, finetune translation, understand novel mechanisms of action, combat off-target toxicities and streamline manufacturing processes. (Source: World ADC London 2024)
